Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EG...
Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
About this item
Full title
Author / Creator
Publisher
Chichester, UK: John Wiley & Sons, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Chichester, UK: John Wiley & Sons, Ltd
Subjects
More information
Scope and Contents
Contents
Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR‐sensitive and EGFR T790M‐resistant mutations. Patients with pre‐treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR‐TKIs, whereas osimertinib has positive effects. Howeve...
Alternative Titles
Full title
Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0cedb960beee460a9f83e1aa6f61dd01
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0cedb960beee460a9f83e1aa6f61dd01
Other Identifiers
ISSN
2051-3380
E-ISSN
2051-3380
DOI
10.1002/rcr2.759
